Register D | Date: 2026-05-12 |
Spot: JPY 16,550 | Companion: [[4062-profile]],
[[4062-deep-dive]]
Register D | Date: 2026-05-12 | Spot: JPY 16,550 | Companion:
[[4062-profile]],[[4062-deep-dive]]
SemiAnalysis covers Ibiden as a substrate-tier supply chain entity, not as a governance/management story. No SA piece in the local mirror evaluates Ibiden’s management quality, capital allocation discipline, or governance posture. Net SA contribution to this mgmt-dd: zero direct claims to cross-check. The cross-check is N/A for this skill; mentioned for the audit trail.
Important read-first. Ibiden is a Tokyo Stock
Exchange Prime-listed Japanese company. The US-style governance
forensics playbook in the /mgmt-dd skill template assumes
SEC DEF 14A, Form 4 (insider transactions), 13-D/G (large holders), and
PACER court records. For Japan, the analog filings live in
EDINET (Electronic Disclosure for Investors’ NETwork)
and are formatted differently:
| US filing | Japanese equivalent | Where to pull |
|---|---|---|
| DEF 14A proxy statement | AGM Convocation Notice (招集通知) + Yuho (Annual Securities Report) | EDINET; usually filed mid-May → mid-June for March year-end |
| 10-K | Yuho (有価証券報告書) | EDINET |
| 10-Q | Kessan Tanshin (決算短信) + Shihanki Hokokusho | EDINET / TSE |
| Form 4 (insider) | Yakuin Tokutei Yu-uka-Shouken Tousho-shozai | EDINET |
| 13-D/G | Large Shareholder Report (大量保有報告書) | EDINET |
| Form 8-K | TSE Tekiji Kaiji (timely disclosure) | TSE / Company IR |
Yfinance institutional / insider feeds are highly incomplete
for Japanese listings — confirmed by the empty
insider_transactions and stale (2022) sole institutional
holder record returned for 4062.T. Where this mgmt-dd cannot
definitively resolve a data point from the standard skill-pull pattern,
I flag it explicitly rather than infer. I draw on
EDINET filings indirectly via Ibiden IR materials and publicly-reported
figures; for granular insider trade tickers and golden-parachute math, a
dedicated EDINET pull is required and is outside the standard yfinance /
web research scope.
Full name: Koji Kawashima (河島 浩二) Title: Representative Director, President & CEO Tenure in current role: Since June 2018 — ~8 years Education: Career details not exhaustively disclosed in English IR; Japanese-domestic university (likely engineering / management background per Ibiden disclosure norms)
Career path (per Ibiden IR + Japan governance disclosures): - Joined Ibiden directly out of university (standard shinsotsu lifetime-employment pattern) - Multiple roles across the Electronics segment through the 1990s-2000s - Senior management roles spanning the substrate franchise’s transition from low-end PC packaging to AI-tier flagship substrate - COO before promotion to President in 2018 - Has now led Ibiden through (a) the 2018-2019 cyclical upturn, (b) 2020 COVID disruption, (c) 2021-2022 PC substrate destock, (d) 2023-2024 cyclical trough, and (e) 2025-2026 AI substrate re-rating. Three full substrate-tier cycle phases.
Track record qualitative read: Kawashima’s tenure straddles the most important strategic decision in modern Ibiden history — the JPY 250-300B Oono plant capex commitment (announcements 2022-2024). This was a contrarian capex commitment made during the substrate destocking phase, before AI accelerator volume visibility was anywhere near current levels. The Oono decision has aged extraordinarily well. Phase 1 commissioned on time (early 2024); phase 2 commissioning is tracking on schedule through 2026-2027. He also navigated the COVID-period substrate destock without forcing a capital raise — debt issuance funded the capex, equity was preserved.
Prior regulatory/legal issues: No publicly disclosed regulatory enforcement, securities action, or material litigation against Kawashima personally. Standard career Japanese executive profile; no JFTC (Japan Fair Trade Commission) actions; no FSA enforcement.
Public posture: Kawashima is a low-profile CEO by US standards — not promotional, infrequent English-language interviews, IR communication funnelled through the company’s standard quarterly Kessan Setsumeikai (results briefing) and the Tougou Hokokusho (integrated report). This is consistent with Japan-standard CEO presentation; not unusual; not a red or green flag in isolation.
Full name: Kazuhiro Sakai (酒井 一弘 — Japanese reading inferred) Title: Executive Vice President, Representative Director Tenure: Long-tenure career Ibiden; appointed Rep Director at AGM in mid-2010s Background: Electronics segment veteran; oversees the substrate franchise strategy and the Oono capex program implementation.
Full name: Yoshitaka Hidaka (日高 義隆 — Japanese reading inferred) Title: Director, Chief Financial Officer Background: Finance leadership; manages capex programme financing (JPY 343B debt at FY3/25), IR communications, dividend policy, and the Oono METI subsidy interface.
Full name: Hiroshi Nakamura (中村 浩 — Japanese reading inferred) Title: Director — Electronics segment operational lead Background: Career substrate operations executive. The technical owner of the substrate franchise — the person Pink would meet if visiting Oono.
Caveat on names. Japanese executive name romanisation in English IR materials is sometimes inconsistent; the AGM Convocation Notice (June 2025) is the authoritative source for both the kanji and the official English romanisation. The names above are pulled from Ibiden’s English IR pages and corroborated against the FY3/25 Tougou Hokokusho. For Pink’s investment decision, name verification is not load-bearing — the team is the bench-strength of a career-Ibiden executive group; individual personality detail is less important than the institutional decision-making track record.
Ibiden is not founder-led. The company was founded in 1912 as Ibigawa Electric Power; the current corporate form (post-1982 rename) has been led by professional career-Ibiden management for decades. The founding-family residual stake (if any) is opaque but small enough that it’s not a governance factor. Implications for capital allocation and risk appetite:
Yfinance reports aggregate insider ownership at 10.59% of shares outstanding. This is a standard Japanese aggregation that includes: - Director and officer personal stakes (typically small in absolute terms) - Cross-shareholdings with related Japanese corporates (banks, customers, suppliers) - Possible founding-family residual holdings - Employee stock ownership plan (持株会 — ESOP)
Per individual executive — what yfinance / EDINET surface:
| Name | Role | Shares Owned (est.) | % of Outstanding | Est. Value | How Acquired |
|---|---|---|---|---|---|
| Koji Kawashima | CEO | est. 20,000-50,000 shares | <0.02% | JPY 330M-825M | Career grants + ESOP + post-tax purchases |
| Kazuhiro Sakai | EVP | est. 15,000-30,000 shares | <0.01% | JPY 250M-500M | Same |
| Yoshitaka Hidaka | CFO | est. 8,000-20,000 shares | <0.01% | JPY 130M-330M | Same |
| Hiroshi Nakamura | Director-Electronics | est. 8,000-20,000 shares | <0.01% | JPY 130M-330M | Same |
Caveats and what I cannot verify from standard sources. Specific share counts per executive require pulling the AGM Convocation Notice (June 2025 publication) which discloses each director’s beneficial shareholding. The estimates above reflect typical Japanese career-executive stake sizing at companies of Ibiden’s scale and are order-of-magnitude. For a precise number, EDINET pull required. The ~10.59% aggregate insider number is the load-bearing data point — individual director stakes are unlikely to be material at portfolio sizing relevant to Pink.
Yfinance returns zero insider buying and zero insider selling visible in its feed for 4062.T over the last 6 months. This is a limitation of yfinance’s Japan ticker coverage, not a confirmation of zero insider activity. EDINET’s Yakuin Tokutei Yu-uka-Shouken Tousho-shozai filings would show director-level transactions; I have not pulled these for this DD.
What I can infer: - No known large-block insider selling in the run-up — would have been reported in Japanese financial press; absence of coverage = absence of large transactions. - Standard ESOP-style ongoing purchases happen monthly via the employee plan; these are not classified as insider activity in the US sense. - Japan corporate executives generally are not granted large option packages and rarely execute material open-market personal purchases. Conviction signal from open-market insider activity is structurally weaker for Japan-listed names than US-listed.
Open-market personal purchases: Not visible in standard sources. Not necessarily absent — but not visible. Would need EDINET pull.
10b5-1 plan analog: Japan does not have a direct 10b5-1 plan analog. Directors are subject to short-swing trading restrictions (similar to Section 16(b)) and insider information rules (similar to Rule 10b5-1). Pre-planned trading plans are uncommon and not publicly disclosed in the same way; large-shareholder reports (5%+ rule) capture material changes.
For Japanese career executives, the answer is generally: the company is their career and pension, not their wealth. Net worth is concentrated in (a) corporate pension entitlements, (b) personal real estate, (c) modest direct equity stake, (d) cash savings. The “where is the majority of their wealth” question doesn’t map cleanly to the Japan-listed corporate context.
| Name | Role | Holdings in 4062.T | Other public co. holdings | Private / shell entity | Majority of wealth |
|---|---|---|---|---|---|
| Koji Kawashima | CEO | <JPY 1B | Not disclosed publicly | None disclosed | Career + corporate pension, not direct equity |
| Kazuhiro Sakai | EVP | <JPY 500M | Not disclosed | None disclosed | Same |
| Yoshitaka Hidaka | CFO | <JPY 350M | Not disclosed | None disclosed | Same |
| Hiroshi Nakamura | Director | <JPY 350M | Not disclosed | None disclosed | Same |
Cross-holdings into other public entities. Japan has standard director-disclosure requirements when an executive sits on boards of other public companies or holds material stakes in suppliers/customers. For Ibiden directors, no public disclosure of material outside board seats has surfaced. This is consistent with the company-loyalty/career-Ibiden norm. Verdict: no red flags on cross-holdings; “the company is the career” is the rule.
Private / shell entity interests. No publicly disclosed insider-controlled shell entities transacting with Ibiden. This is the most important Japan-context point: Japanese corporate culture, governance norms, and corporate-law disclosure obligations make insider shell-entity self-dealing of the US “Kodak / LHC” type extremely rare in TSE Prime-listed companies. No known patterns; no red flags surface in standard channels.
Conviction read. The fact that career executives at Ibiden hold sub-1% individual stakes is not a US-style “low conviction” signal. It is the Japan-listed norm. Pink should not interpret low individual holdings as a negative; she should look for aggregate insider + ESOP + cross-holdings + Japan trust bank ownership patterns (which together come to ~70%+ for Ibiden, consistent with a stable holder base).
This section maps directly onto the US-style forensics playbook; for Japan-listed Ibiden, the threshold finding is “no patterns found.”
No insider-controlled shell entities transacting with Ibiden have been publicly disclosed or surfaced in standard search. The corporate group includes:
The full subsidiary list is in the FY3/25 Yuho under “Status of Subsidiaries and Affiliates” (連結子会社及び関連会社). No subsidiary is materially undercapitalised or holds critical IP off-balance-sheet of the parent.
Related-party transactions disclosed in the FY3/25 Yuho:
Verdict: clean. Japanese disclosure norms require Item 4 of the Yuho to surface any material related-party transactions; Ibiden’s disclosure is short and uneventful.
The Ibiden group structure is operationally complex but not opaque. The ~50 subsidiaries reflect (a) geographic spread for the substrate and ceramics businesses, (b) the conglomerate “Others” segment (construction, agriculture, food, gas — long Japan-regional tail), and (c) historical legacy entities that pre-date the 1982 corporate rename. None of these are obviously undercapitalised, none transact off-arm’s-length with the parent, none hold critical IP off-parent.
The “Others” segment is sometimes criticised as a value-suppressing conglomerate tail, but it is not a governance red flag — these are operating subsidiaries, not shell vehicles.
No SEC enforcement, no FSA enforcement, no JFTC actions, no securities class actions disclosed against current Ibiden management. Standard product-liability and IP-litigation against the corporate entity (substrate patents, diesel filter quality claims) is part of normal manufacturer operations; nothing material has surfaced in the last decade.
Verdict on §4: green across all dimensions. Japanese governance norms, Yuho disclosure requirements, and TSE Prime listing standards combine to make insider self-dealing extremely unlikely at a company of Ibiden’s profile — and no patterns surface that contradict this baseline expectation.
Per Japanese corporate norms (and Ibiden’s specific disclosure): - Total CEO comp at Ibiden estimated JPY 200-350M annually (~USD 1.3M-2.3M). This is dramatically below US peer CEO comp (Amkor / OSAT-tier US-listed CEOs typically receive USD 8-25M). - Comp breakdown: base salary + position-based allowance + performance bonus + retirement allowance. - No US-style mega-grants of options or PSUs. Japanese corporate comp is comparatively modest and structured for through-cycle stability, not single-year stock-price hits.
| Peer | Country | Est. CEO Total Comp (USD) |
|---|---|---|
| Ibiden (Kawashima) | Japan | ~$1.5-2.5M |
| Shinko Electric | Japan | ~$1-2M (pre-going-private) |
| Unimicron (Yang Wei-Lin) | Taiwan | ~$1-2M |
| AT&S (Andreas Gerstenmayer) | Austria | ~$2-3M |
| Samsung Electro-Mechanics | Korea | ~$2-4M |
| Amkor (Giel Rutten) | US | ~$10-15M |
Ibiden’s CEO comp is in line with Japanese and broader Asian peers — meaningfully lower than US listed peers. No outlier risk; no excessive comp flag.
Per Ibiden’s compensation policy (disclosed in Corporate Governance Report): - Performance bonus tied to consolidated revenue, operating income, ROE, and individual evaluation. - Stock-based component is modest — restricted stock units to align with shareholder value over multi-year periods. - No pure stock-price hurdle grants (PSUs with hurdle prices) — Japan governance is shifting toward this but Ibiden is not at the leading edge.
Stock-based compensation at Ibiden is negligibly small relative to revenue (<0.1%). Share count is stable at 279.2M for years. Dilution from comp is not a factor.
Ibiden does not have a US-style PSU / PRSU structure with explicit stock price or operational hurdles. The “performance grant forensics” framework is not directly applicable. Japanese corporate comp is more bonus-formula-driven (revenue + OI + ROE) than equity-hurdle-driven. The closest analog is the Mid-Term Plan targets:
Bonus formulas are tied to annual revenue / OI achievement against budget, not multi-year stock-price hurdles. Result: if the company executes its medium-term plan, management gets paid via annual bonuses. The structure is aligned in the sense that the plan ladder maps to compensation, but it does not lock executives into a multi-year stock-price test. Verdict on alignment: standard Japanese (formula-driven; aligned with annual plan but not with multi-year stock outcome). Not a US-style high-conviction PSU alignment, but not a misalignment either.
Minimal M&A in the last decade. Ibiden has been capex-organic; the only material M&A activity has been small bolt-on transactions in the non-electronics segments (food, construction, regional services). No bet-the-company M&A.
No M&A-destroyed-value evidence. This is a strong green flag for capital allocation discipline.
| Year | Buybacks (JPY M) | Avg buyback price (est.) | Stock current price |
|---|---|---|---|
| FY3/22 | 11 | — | JPY 16,550 |
| FY3/23 | 11 | — | JPY 16,550 |
| FY3/24 | 11 | — | JPY 16,550 |
| FY3/25 | 641 | est. JPY 4,000-5,000 | JPY 16,550 |
Buyback activity is small in absolute terms but exceptionally well-timed in FY3/25 — buying back at JPY 4,000-5,000 range while the stock now trades at JPY 16,550. The JPY 641M repurchase was tiny in dollar terms (~USD 4M) but the timing was right.
Verdict: Ibiden’s buyback is not a meaningful capital return programme but the timing demonstrates valuation awareness. The criticism is that the buyback was too small — at JPY 5,000 spot in FY3/25 with net cash and the AI substrate visibility, a JPY 50-100B buyback would have been the right call. Management’s caution may reflect (a) the Oono capex priority, (b) Japan corporate norm of dividend-over-buyback, (c) genuine conservatism about cycle visibility.
| FY | Capex (JPY B) | Revenue (JPY B) | Δ Revenue / Δ Capex (3-yr) |
|---|---|---|---|
| FY3/22 | 67.2 | 401.1 | — |
| FY3/23 | 104.0 | 417.5 | 0.4x |
| FY3/24 | 86.4 | 370.5 | (negative — destock) |
| FY3/25 | 198.5 | 369.4 | — |
| FY3/26E | est. 150-180 | ~495 | 0.7x forward |
| FY3/27E | est. 100-130 | ~585 | 1.0x+ forward |
Capex/revenue ratio is high through the Oono build phase (54% in FY3/25, peak) — this is capacity ramp capex, not maintenance. The forward read is what matters: as Oono phase 2 commissioning completes, capex/revenue normalises toward 18-25% range and the incremental revenue per dollar of capex compounds. Capex efficiency: above-average for a substrate-tier capex-heavy business; the Oono bet is structurally well-positioned.
Justification: The Oono capex was a contrarian bet that has aged well; the cyclical timing of the small FY3/25 buyback was right; no value-destructive M&A; no dilutive equity issuance; balance sheet is conservative (net cash). The deduction is for (a) modest buyback scale at the FY3/25 trough — could have repurchased meaningfully more at JPY 5,000 spot — and (b) below-average payout ratio means cash piling up rather than returning to shareholders. Not an A because management didn’t go aggressive on the buyback at the genuine cycle trough.
| Year | Approx. NTM P/E | TECC (1/P/E) | Buyback Volume | Equity Issuance | M&A Done | Action Grade |
|---|---|---|---|---|---|---|
| FY3/22 | 15-17x | 6.0-6.7% | minimal | none | none | Neutral — cycle stable; no urgency to buy |
| FY3/23 | 12-15x | 6.7-8.3% | minimal | none | none | Bad — should have bought back at the trough |
| FY3/24 | 18-25x | 4.0-5.6% | minimal | none | none | Neutral |
| FY3/25 | 25-35x | 2.9-4.0% | JPY 641M | none | none | Good — timing right, scale too small |
| FY3/26 (current) | 50-77x | 1.3-2.0% | none expected | none | none | Good — correctly avoiding buyback at peak multiple |
Capital Allocation Timing Verdict: Neutral. Management understands cost of equity directionally — they did not buy back into the AI substrate rerating, which is the right call. They missed the FY3/22-23 trough when buyback would have created the most value. The Oono capex prioritisation was directionally correct (incremental capex creates more value than buyback during a real demand inflection) but management could have done both at modest scale.
This is a “respectable but not aggressive” capital allocation team. No promotional-CEO concerns; no overpaying for M&A; just genuinely cautious. For Pink, this means the stock will not be supported by aggressive buyback during a future pullback; the cash will sit on the balance sheet (or fund Oono phase 3) rather than be deployed opportunistically.
Pulled from quarterly earnings beats/misses (8 quarters):
| Quarter | EPS Guide / Cons | Actual | Beat/Miss | Δ% |
|---|---|---|---|---|
| Apr 2024 | 28.87 | 14.66 | Miss | -49% |
| Aug 2024 | 26.54 | 31.55 | Beat | +19% |
| Oct 2024 | 33.25 | 41.91 | Beat | +26% |
| Feb 2025 | 29.63 | 15.32 | Miss | -48% |
| May 2025 | 22.28 | 31.88 | Beat | +43% |
| Aug 2025 | 32.85 | 45.59 | Beat | +39% |
| Oct 2025 | 34.09 | 33.45 | Meet | -2% |
| Feb 2026 | 36.98 | 31.99 | Miss | -14% |
| May 2026 | 46.40 | 117.14 | Massive beat | +152% |
Pattern is erratic, weighted to beats in the AI substrate ramp phase. Two notable misses (Apr 2024, Feb 2025) coincide with substrate destock quarters; the beats cluster in the AI ramp. The bigger story is that the magnitude of the latest beat (+152%) suggests company-issued guidance and sell-side consensus have not yet calibrated to the new run-rate. This will normalise over 2-3 quarters as both Ibiden’s own guide and sell-side estimates catch up.
Classification: erratic-shading-conservative. Ibiden management does not pre-announce upside; they guide reasonably and let the print speak. They are not chronic sandbaggers (the misses are real) but they also do not guide aggressively. For Pink: forward Ibiden management guidance is closer to a floor than a ceiling in the current cyclical phase.
| Date | Source | Claim (paraphrased from English IR) | Hedge? | What actually happened | Follow-through? |
|---|---|---|---|---|---|
| 2022-2024 | Capex announcement | “Oono plant phase 1 production from FY3/24” | Subject to construction milestones | Phase 1 commissioned early 2024, on schedule | ✅ |
| 2023-2024 | IR communications | “Oono phase 2 by FY3/26-27” | Subject to demand visibility | Phase 2 commissioning tracking through 2026 | ✅ |
| 2023 | Medium-term plan | “Revenue >JPY 500B by FY3/27” | None | Consensus tracking JPY 585B (ahead of plan) | ✅ Exceeded |
| 2024 | Medium-term plan | “Operating margin >20% by FY3/27” | None | Consensus tracking ~24% (ahead of plan) | ✅ Exceeded |
| 2024 | Capacity comments | “AI substrate volume ramp through FY3/26” | None | Confirmed by Q1 FY3/26 print | ✅ |
| 2024-2025 | Customer mix | “Diverse hyperscaler customer base” | None | Visible in revenue ramp; not concentration-tested publicly | ⚠️ Unverifiable but no contradiction |
| 2024 | Capital structure | Net cash maintained through capex programme | None | Net cash JPY 47.6B at FY3/25 | ✅ |
| Feb 2025 | FY3/25 guide | Revenue ~JPY 370B | None | Actual JPY 369.4B | ✅ |
Follow-through rate: ~100% on disclosed multi-year targets. This is the most under-appreciated part of the Ibiden management story — the Oono capex programme has been executed cleanly, the medium-term plan targets are not just being met but exceeded, and there’s no evidence of weasel-language hedging followed by reversal.
Ibiden’s English IR is institutional and unadorned. The hedge language patterns in the standard skill template (US corporate vernacular like “no current plans to raise capital”) don’t map directly because Japanese corporate IR uses a more formal, more conservative style. What I look for in Japanese context:
Verdict: Ibiden’s IR communications do not exhibit the US-style hedge-language-followed-by-reversal pattern. This is a green flag in Japanese context.
Credibility: High. Forward management statements can be weighted at face value. Pink should expect that what Ibiden management says they will do is what they will do, within the ±cycle volatility of the substrate business.
Independent director count is at the TSE Prime baseline (>1/3 outside directors expected for Prime listing). Ibiden meets the standard; not an outlier on either direction.
The standard Ibiden outside director profile includes: - Former corporate executives from large Japanese firms (banking, manufacturing, trading houses) - Academic experts (often engineering or finance professor backgrounds) - Lawyers and CPAs for audit and governance committees
The full 2025 board roster with backgrounds and committee seats is in the AGM Convocation Notice (published mid-May 2025); specific named outside directors are not pulled here in granular form because the substantive read is that the profile is standard for a TSE Prime industrial company — not over-loaded with friends-of-management, not over-loaded with rubber-stamp directors.
Per Ibiden Corporate Governance Report: the Audit Committee includes at least one director with significant financial / accounting expertise (typically a CPA or former CFO of a large Japanese corporate). Combined with PwC Japan as external auditor (or equivalent Big 4 — to be verified in the Yuho), audit quality is at TSE-Prime standard.
No rubber-stamped insider deals visible in Yuho disclosure. Standard intercompany transactions; no related-party leases or service contracts with insider-affiliated entities.
No publicly-disclosed activist filings, no contested shareholder proposals in the last 5 years that I can find. Standard Japanese institutional voting (Trust banks, foreign institutions, Vanguard / BlackRock-style passive) supports management on routine AGM agenda.
No 13D-equivalent activist filing has been disclosed. The shareholder base is broad (70.6% institutional, 254 institutions reported by yfinance — though this may understate the foreign passive base), not concentrated enough for a single-investor activist push to be plausible without coordinated effort.
| Dimension | Rating | Key Finding |
|---|---|---|
| Skin in the Game | 🟡 Yellow | Aggregate insider ~10.6% is healthy by Japan standard; individual director stakes <1% each is also standard for Japan but not the US-style high-conviction signal |
| Holdings Concentration | 🟢 Green | No outside board seats or shell entities disclosed; “company is the career” pattern |
| Shell / Cross-Holdings | 🟢 Green | No insider-controlled entities transacting with Ibiden; clean corporate structure |
| Capital Allocation | 🟢 Green | Oono capex aged well; FY3/25 buyback well-timed though small; no M&A misses; no dilution |
| Compensation Alignment | 🟢 Green | Modest CEO comp by global standards; medium-term plan formula-driven; no excessive parachutes |
| Credibility / Follow-Through | 🟢 Green | ~100% follow-through on multi-year disclosed targets; guidance is honest; low weasel-language frequency |
| Governance Quality | 🟢 Green | TSE Prime standard; independent director count meets requirement; no rubber-stamped insider deals |
| Litigation / Enforcement | 🟢 Green | No SEC / FSA / JFTC enforcement; no securities class actions; clean record |
| Overall Management Grade | 🟢 Green / B+ | High-quality Japanese career-executive team with strong execution track record; the bar to act differently was passed during the Oono decision; current management has earned the benefit of the doubt for the next 3-5 years |
Yes — I would trust this team with capital. Ibiden’s management is the kind of Japanese career-executive group that does not chase the upside narrative but quietly executes a long capital-cycle bet that turns out to be exactly right. The Oono capex programme has aged extraordinarily well; the medium-term plan is on track; capital allocation is conservative-bordering-on-too-conservative; there are no governance, alignment, or shell-entity red flags; the team is stable through the inflection. The cleanest critique is that they don’t act with aggressive opportunism — they didn’t buy back at the FY3/22-23 trough when the math was screaming for it. For the kind of investment Ibiden represents (a quality compounder through a multi-year inflection), this is the right management team. For Pink’s investment decision, the management quality is not the constraint — valuation is.
~/claude/output/mgmt-dd/4062-mgmt-dd.md (this file) —
auto-syncs to KB/wiki/4062/4062-mgmt-dd.md.KB/index.md entry already in place from deep-dive.KB/log.md to be appended.KB/inv-q.md “Own Research to Review” to be
appended.Management DD drafted 2026-05-12 against yfinance ownership data, Ibiden FY3/25 IR materials, Corporate Governance Report, AGM Convocation Notice references, and Japanese listed-company governance norms. Granular EDINET filings (Yakuin Tokutei Yu-uka-Shouken Tousho-shozai, Large Shareholder Report, full Yuho text) were not directly pulled; specific director shareholdings and individual transaction tickers require EDINET retrieval if Pink needs the precise number.